ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Lung Cancer

Older Early-Stage NSCLC Patients Benefit From Adjuvant Chemotherapy

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection. Image © pruit phatsrivong / Shutterstock.com.

Lung Cancer

Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.

Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.

The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.

Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.

In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).

A phase I study showed that transcriptional inhibitor PM01183 with doxorubicin induced responses in patients with small-cell lung cancer.

The platinum compound nedaplatin in combination with docetaxel improved outcomes over cisplatin and docetaxel in advanced squamous cell carcinoma of the lung.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.